Product Development Catalysts To Look Out For This Quarter
This article was originally published in Scrip
Executive Summary
The last quarter of this year will see major catalyst events for around 20 drugs, latest research from Sagient's BioMedTracker shows. Big pharma companies expecting data read-outs or regulatory action before Christmas include both Mercks, AstraZeneca and AbbVie, while advances are expected for three treatments for pancreatic cancer and two novel antibiotics, among others.